(AOF) – The Paredes group proposed on June 21, 2023 to the two main shareholders of Orapi to form a new integrated entity. Mr. Guy Chifflot, the founder and first shareholder of Orapi, directly and indirectly via the companies La Financière MG3.F. and GC Consult, agreed to sell to Paredes its 2,315,265 shares representing 34.8% of the capital and its 2,242,763 ORA 2 (bonds redeemable in shares) potentially representing an additional 11.5% of the capital, once redeemed in shares .
Following additional discussions aimed at strengthening the attractiveness of the offer vis-à-vis all shareholders, Paredes made a new offer to the Chifflot Group on July 25, 2023 based on a price per share increased to 6.50 euros (against 5.88 euros previously, an improvement of 11%).
This offer is also based on a price per ORA 2 adjusted to their nominal value, ie 5.20 euros (compared to 5.88 euros previously).
This improved offer primarily benefits small holders and funds advised by Kartesia Management Sàrl, which do not have for the first, and in a limited proportion for the second, ORA 2.
It represents a constructive approach by Paredes vis-à-vis all shareholders, which improves its offer compared to that announced on June 27 and 28, 2023 and is now based on an enterprise value of 80 million euros, i.e. more than 8.3x the pre-IFRS 16 EBITDA (which is the real indicator of cash generation) achieved by the Orapi group in 2022, i.e. 9.7 million euros.
AOF – LEARN MORE
Find out more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in financing by venture capital for start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemicals) or 13 years (biologicals), with discounts that could range from 35 to 60% for biotechs. Similarly, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.